Financial Performance - In 2024, net revenue increased by 35% to $117,615,000 compared to $87,241,000 in 2023[342]. - Gross profit for 2024 was $25,198,000, representing a 112% increase from $11,909,000 in 2023[343]. - The company reported an operating loss of $76,529,000 in 2024, an improvement from a loss of $84,800,000 in 2023[342]. - For 2024, consolidated net revenue was $117.6 million, an increase of $30.4 million from 2023, driven by higher cannabis flower and extract sales in Canada and other countries[344]. - Consolidated cost of sales for 2024 was $91.7 million, reflecting a $17.2 million increase from 2023, primarily due to inventory step-up from the Cronos GrowCo Transaction[345]. - Net income for 2024 was $40.0 million, a substantial improvement from a net loss of $74.6 million in 2023[356]. - Adjusted EBITDA for 2024 was $(34,942,000), an improvement from $(61,564,000) in 2023[373]. - The company reported a foreign currency transaction gain of $57.9 million in 2024, a significant increase from a loss of $7.3 million in 2023[363]. - The company recognized a loss on held-for-sale assets of $11.2 million in 2024, reflecting a strategic shift in asset marketing[364]. - For the year ended December 31, 2024, the company reported a net income of $40,022,000, compared to a net loss of $70,439,000 in 2023[372]. Operational Changes - The company exited its U.S. hemp-derived cannabinoid product operations in Q2 2023, marking a strategic shift that significantly impacted financial results[323]. - Cronos launched new products in 2024, including Spinach Grindz™ and SOURZ by Spinach gummies, expanding its offerings in the edible and vape categories[328]. - The Cronos GrowCo transaction, completed in July 2024, allows the company to consolidate operations and expand its cannabis supply capabilities[322]. - Cronos expects to complete the expansion of the Cronos GrowCo facility by Q2 2025, with the first harvests anticipated in the second half of 2025[334]. - The company plans to wind down the Cronos Fermentation facility and list it for sale, indicating a strategic shift in operations[404]. - The company has transitioned to a single operating segment following the exit of its U.S. operations in Q2 2023, with all prior segment disclosures reclassified accordingly[510]. Investment and Assets - Cash and cash equivalents increased by 28% to $858.8 million as of December 31, 2024, compared to $669.3 million in 2023, with a constant currency increase of 30% to $869.8 million[385]. - The company reported total assets of $1,166,312,000 as of December 31, 2024, an increase from $1,140,266,000 in 2023, representing a growth of approximately 2.3%[453]. - The total liabilities rose to $55,330,000 in 2024, compared to $44,142,000 in 2023, indicating an increase of approximately 25.3%[453]. - Shareholders' equity attributable to Cronos Group decreased to $1,064,063,000 in 2024 from $1,099,571,000 in 2023, a decline of about 3.2%[453]. - The company acquired majority control of Cronos Growing Company Inc. on July 1, 2024, which was classified as a business combination under ASC 805[427]. - The valuation of the net assets of Cronos Growing Company involved significant assumptions including real estate appraisals and forecasted revenues, which required substantial auditor judgment[428]. Research and Development - Research and development expenses decreased to $4.2 million in 2024, down $1.6 million from 2023, due to lower collaboration costs[350]. - The Company has a research and development center in Canada focusing on cannabinoids, with ongoing initiatives around rare cannabinoids and a collaboration with Ginkgo for cultured cannabinoids[494]. Market Expansion - In 2024, Cronos expanded its international footprint by entering the UK market with the PEACE NATURALS brand[331]. - The company plans to continue focusing on market expansion and new product development as part of its strategic initiatives[375]. Financial Adjustments - Operating expenses totaled $101.7 million for 2024, a 5% increase from 2023, with significant impairment loss on long-lived assets rising to $16.4 million[348][355]. - The impairment loss on long-lived assets for 2024 included $14,258,000 related to the write-down of Ginkgo Exclusive Licenses[373]. - The company incurred transaction costs of $701,000 related to the Cronos GrowCo Transaction in 2024[373]. - The company recognized uncertain tax positions only if they are more likely than not to be sustained upon examination by tax authorities[508]. Currency and Interest - Interest income for 2024 was $52.0 million, up $0.8 million from 2023, mainly due to higher interest rates[357]. - A 10% change in the interest rate in effect for 2024 would affect interest income by approximately $5.2 million[412]. - The company experienced a foreign currency loss of $(86.3) million for the year ended December 31, 2024, compared to a gain of $21.5 million in 2023[414]. - A 10% change in the exchange rates for the Canadian dollar would affect the carrying amount of net assets by approximately $40.1 million as of December 31, 2024[414].

Exhibit 99.1 Cronos Group Reports 2024 Fourth Quarter and Full-Year Results Net revenue in Q4 2024 increased by 27% year-over-year to $30.3 million; Net revenue in FY 2024 increased by 35% year-over-year to $117.6 million Spinach Ends 2024 as the Number One Cannabis Brand in Canada ® 1 "From Spinach becoming the number one cannabis brand in Canada and PEACE NATURALS achieving a number one position in Israel, to our groundbreaking advancements in cannabis genetics, to international expansion, Cronos is well- ...

Net revenue in Q4 2024 increased by 27% year-over-year to $30.3 million; Net revenue in FY 2024 increased by 35% year-over-year to $117.6 million Spinach® Ends 2024 as the Number One Cannabis Brand in Canada1 PEACE NATURALS® Ends 2024 as the Number One Cannabis Brand in Israel 2 Industry leading balance sheet with $859 million in cash and cash equivalents TORONTO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), today announced its 2024 fourth quar ...

Core Viewpoint - Cronos Group Inc. will hold its 2024 fourth-quarter and full-year earnings conference call on February 27, 2025, at 8:30 a.m. ET, where senior management will discuss financial results and answer questions from the investment community [1] Group 1: Conference Call Details - Participants can register for the conference call or webcast online and are encouraged to dial in fifteen minutes early to avoid delays [2] - The webcast will be archived for replay on the Company's website [2] Group 2: Company Overview - Cronos is a global cannabinoid company focused on advancing cannabis research, technology, and product development [3] - The Company aims to build a disruptive intellectual property and an iconic brand portfolio, which includes brands like Spinach, PEACE NATURALS, and Lord Jones [3]

Core Viewpoint - Cronos Group's stock experienced a significant increase of 9.4% following the announcement of Q3 earnings that exceeded Wall Street expectations, raising questions about the sustainability of this performance and potential exit strategies for investors [1][4]. Group 1: Q3 Earnings Performance - Cronos reported Q3 sales of approximately $34.3 million, surpassing analyst expectations of $24.8 million, and achieved a profit of $0.02 per share, contrary to predictions of a loss of $0.01 per share [1][2]. - Year-over-year sales growth was 38%, with the "Spinach" brand becoming the top recreational cannabis brand in Canada, and the "Peace Naturals" brand leading in the medical marijuana market in Israel [2]. Group 2: Future Outlook and Guidance - The company aims to reduce operating costs by $5 million to $10 million this year, focusing on savings in general and administrative expenses, sales and marketing, and research and development [3]. - Despite the positive Q3 results, Cronos remains unprofitable for the first three quarters of the year, and analysts project continued net losses through 2033, indicating skepticism about the company's ability to achieve consistent profitability [3][4].

Financial Data and Key Metrics Changes - Cronos Group reported its financial results for Q3 2024, with specific metrics detailed in the earnings release [3][4]. - The company may refer to non-GAAP financial measures during the call, which are subject to risks and uncertainties [4][5]. Business Line Data and Key Metrics Changes - Specific performance metrics for each business line were not detailed in the provided content [3]. Market Data and Key Metrics Changes - Market performance data and key metrics were not provided in the available content [3]. Company Strategy and Development Direction and Industry Competition - The company is focused on strategic initiatives as discussed by the Chief Strategy Officer, but specific strategies were not detailed in the provided content [3]. Management's Comments on Operating Environment and Future Outlook - Management may provide insights on the operating environment and future outlook, but specific comments were not included in the available content [4][5]. Other Important Information - The earnings materials and SEC filings are available on the company's website for further details [5]. Q&A Session All Questions and Answers - No specific questions and answers from the Q&A session were provided in the available content [3].

Operational Changes - The company is undergoing a wind-down of operations at its Winnipeg facility, which is expected to yield cost savings and operational efficiencies [98]. - The company has exited its U.S. hemp-derived cannabinoid product operations, incurring associated costs and write-offs [98]. - The company is focusing on expanding Cronos GrowCo's purpose-built cannabis facility to enhance production capabilities [102]. - The company is exploring the potential success of joint ventures and strategic alliances to drive revenue growth [102]. - The company is assessing the impact of the ongoing Middle East Conflict on its operations and product demand in Israel [98]. - The company is evaluating the effects of the Anti-Dumping Investigation on its operations in Israel [102]. - The company is implementing cost-cutting measures as part of a broader realignment strategy to improve financial performance [98]. - The company is committed to differentiating its products through the utilization of rare cannabinoids [100]. - The company is monitoring regulatory developments that may affect its ability to operate in various markets, including potential changes in U.S. cannabis laws [100]. Financial Performance - For the three months ended September 30, 2024, consolidated net revenue was $34.3 million, an increase of $9.5 million (38%) from $24.8 million in the same period of 2023 [123]. - For the nine months ended September 30, 2024, consolidated net revenue reached $87.3 million, representing a $24.0 million (38%) increase from $63.3 million in the same period of 2023 [123]. - The cost of sales for the three months ended September 30, 2024, was $30.3 million, an increase of $10.2 million (51%) from $20.1 million in the same period of 2023 [125]. - The gross profit for the three months ended September 30, 2024, was $3.6 million, a decrease of $0.4 million (9%) from $4.0 million in the same period of 2023 [126]. - The company reported an operating loss of $33.7 million for the three months ended September 30, 2024, compared to a loss of $21.8 million in the same period of 2023 [120]. - The gross margin for the three months ended September 30, 2024, was 11%, down from 16% in the same period of 2023 [122]. - For the three months ended September 30, 2024, total operating expenses were $37.3 million, an increase of 45% compared to $25.7 million for the same period in 2023 [128]. - Sales and marketing expenses for the three months ended September 30, 2024, were $5.5 million, a 4% increase from $5.3 million in the same period last year [129]. - Research and development expenses remained stable at $1.2 million for the three months ended September 30, 2024, but decreased by 27% to $3.2 million for the nine months ended September 30, 2024, compared to $4.4 million in 2023 [130]. - General and administrative expenses decreased by 11% to $12.8 million for the three months ended September 30, 2024, and by 13% to $34.4 million for the nine months ended September 30, 2024, compared to the previous year [131]. - The company recognized an impairment loss on long-lived assets of $14.4 million for the three months ended September 30, 2024, primarily due to the impairment of exclusive licenses [135]. - Interest income, net for the three months ended September 30, 2024, was $12.5 million, a decrease of 7% from $13.4 million in the same period last year, while it increased by 8% to $40.2 million for the nine months ended September 30, 2024 [137]. - The company reported a net income of $7.3 million for the three months ended September 30, 2024, compared to a net loss of $1.8 million in the same period last year, marking a 513% increase [136]. - The gain on revaluation of equity method investment was $32.5 million for both the three and nine months ended September 30, 2024, due to the remeasurement of the investment in Cronos GrowCo [141]. - The company recognized a loss of $10.4 million on held-for-sale assets for both the three and nine months ended September 30, 2024, with no such loss in the same periods of 2023 [145]. - Income tax benefit for the three months ended September 30, 2024, was $2.7 million, up from $1.3 million in the same period of 2023 [146]. - For the nine months ended September 30, 2024, income tax benefit was $5.4 million, compared to $2.9 million for the same period in 2023 [146]. - Adjusted EBITDA for the three months ended September 30, 2024, was $(6.0) million, reflecting ongoing business performance adjustments [149]. - The net loss for the nine months ended September 30, 2024, was $(3.9) million, with total losses including discontinued operations amounting to $(3.9) million [154]. - The company reported a revaluation gain on loan receivable and equity method investment as a result of the Cronos GrowCo Transaction on July 1, 2024 [155]. - The total net loss for the three months ended September 30, 2023, was $(1.8) million, with a significant portion attributed to interest income and depreciation [152]. - Adjusted Gross Profit for the three months ended September 30, 2024, was $10,727,000, a significant increase of 170% compared to $3,970,000 in the prior year [159]. - Gross margin for the three months ended September 30, 2024, decreased to 11% from 16% in the same period of 2023, while Adjusted Gross Margin improved to 31% from 16% [159]. - Operating expenses for the three months ended September 30, 2024, increased by 45% to $37,266,000 from $25,745,000 in the prior year [161]. - Net income from continuing operations for the three months ended September 30, 2024, was $7,324,000, compared to a loss of $1,590,000 in the same period of 2023 [161]. - For the nine months ended September 30, 2024, net revenue was $87,314,000, reflecting a 38% increase from $63,326,000 in the same period of 2023 [163]. - Adjusted EBITDA for the nine months ended September 30, 2024, improved to $(27,739,000) from $(46,774,000) in the prior year, indicating a 41% improvement [163]. - The company recorded an inventory step-up of $7,116,000 related to the Cronos GrowCo Transaction for both the three and nine months ended September 30, 2024 [159]. - For the three months ended September 30, 2024, net revenue was $34.3 million, a 40% increase from $24.8 million in the same period of 2023 [169]. - For the nine months ended September 30, 2024, net revenue was $88.5 million, representing a 40% increase from $63.3 million in the same period of 2023 [169]. - Cannabis flower sales for the three months ended September 30, 2024, were $26.3 million, a 51% increase from $17.4 million in the same period of 2023 [167]. - Gross profit for the three months ended September 30, 2024, was $3.6 million, a 9% decrease from the same period in 2023 [171]. - Operating expenses for the three months ended September 30, 2024, were $38.1 million, a 48% increase from the same period in 2023 [172]. - Net income from continuing operations for the three months ended September 30, 2024, was $8.2 million, an improvement of $9.8 million from the same period in 2023 [173]. - Adjusted EBITDA for the three months ended September 30, 2024, was $(6.5) million, a 57% improvement from the same period in 2023 [174]. - Cash and cash equivalents as of September 30, 2024, were $862 million, sufficient to fund operations over the next twelve months [175]. - Cash generated from operating activities for the nine months ended September 30, 2024, was $11.1 million, compared to cash used of $59.7 million in the same period of 2023 [178]. - Cash generated from investing activities for the nine months ended September 30, 2024, was $180.2 million, a change of $321.6 million from cash used in the same period of 2023 [179]. - A 10% decrease in the interest rate would impact net interest income by $1.4 million for the three months and $4.5 million for the nine months ended September 30, 2024 [187]. - The company reported an Adjusted EBITDA loss of $6.0 million for the three months ended September 30, 2024, an improvement from a loss of $15.2 million in the same period of 2023 [162]. - Constant currency measures indicate a 40% increase in net revenue for the three months ended September 30, 2024, when adjusted for foreign currency fluctuations [161]. - For the nine months ended September 30, 2024, net revenue was $88.5 million, a 40% increase from $63.3 million in the same period of 2023 [169]. - Gross profit for the nine months ended September 30, 2024, was $14.6 million, representing a 46% increase from $10 million in the same period of 2023 [171]. - Operating expenses for the nine months ended September 30, 2024, were $80.4 million, a 10% increase from $73.1 million in the same period of 2023 [172]. - Net income from continuing operations for the three months ended September 30, 2024, was $8.2 million, an improvement of $9.8 million from a loss in the same period of 2023 [173]. - Adjusted EBITDA for the three months ended September 30, 2024, was $(6.5) million, a 57% improvement from $(15.1) million in the same period of 2023 [174]. - Cash and cash equivalents as of September 30, 2024, were $862 million, sufficient to fund operations and capital expenditures for the next twelve months [175]. - Cash generated from operating activities for the nine months ended September 30, 2024, was $11.1 million, compared to cash used of $59.7 million in the same period of 2023 [178]. - Cash generated from investing activities for the nine months ended September 30, 2024, was $180.2 million, a change of $321.6 million from cash used in the same period of 2023 [179]. - The Cronos GrowCo Transaction contributed $4.3 million in cannabis flower sales for both the three and nine months ended September 30, 2024 [169]. - Foreign currency translation resulted in a gain of $12.4 million for the three months ended September 30, 2024, compared to a loss of $20.1 million in the same period of 2023 [186].

Exhibit 99.1 Cronos Group Reports 2024 Third Quarter Results Net revenue in Q3 2024 increased by 38% year-over-year to $34.3 million ® 1 Spinach Becomes the Number One Cannabis Brand in Canada Industry-leading balance sheet with $862 million in cash and cash equivalents TORONTO, November 12, 2024 - Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") today announced its 2024 third quarter business results. "Our results this quarter demonstrate that our long-term strategy is working. With ...

Core Viewpoint - Cronos Group Inc. will hold its third quarter earnings conference call on November 12, 2024, at 8:30 a.m. ET to discuss financial results and answer questions from the investment community [1]. Group 1: Earnings Call Details - The earnings conference call will take place on November 12, 2024, at 8:30 a.m. ET [1]. - Participants can register for the conference call or webcast online and are encouraged to dial in fifteen minutes early to avoid delays [2]. - The webcast will be archived for replay on the Company's website [2]. Group 2: Company Overview - Cronos is a global cannabinoid company focused on advancing cannabis research, technology, and product development [3]. - The Company aims to build a disruptive intellectual property portfolio and elevate the consumer experience through its brand portfolio [3]. - Cronos' brand portfolio includes Spinach®, PEACE NATURALS®, and Lord Jones® [3].

Industry Overview - Recent momentum in marijuana stocks is attributed to increased support for cannabis legalization in the USA, particularly from political figures like Trump [1][2] - Despite federal illegality, over half of the US and other global regions have legalized cannabis, indicating the industry's legitimacy and growth potential [2] Investment Opportunities - The current volatility in marijuana stocks presents opportunities for investors to capitalize on price fluctuations, especially during downtrends [3] - Identifying the best marijuana stocks to buy can lead to significant future profits, particularly when positions are acquired at lower prices [3] Key Companies to Watch - **Tilray Brands, Inc. (NASDAQ: TLRY)**: Engages in research, cultivation, processing, and distribution of medical cannabis products. Recent studies on Fibromyalgia have shown positive results, enhancing its market position [4][5] - **SNDL Inc. (NASDAQ: SNDL)**: Focuses on the production, distribution, and sale of cannabis products in Canada. Recently announced the retirement of its liquor segment president, indicating potential leadership changes [6][7] - **Cronos Group Inc. (NASDAQ: CRON)**: Operates in the cultivation, production, and marketing of cannabis products across Canada, Israel, and Germany. Recently launched new products, including Lord Jones live resin vapes and hash prerolls [7][8][9]